This Annex applies to devices intended for detection or quantification of markers of hepatitis B virus (HBV) infection.
Table 1 applies to first-line assays for hepatitis B surface antigen (HBsAg), and for antibodies against hepatitis B core antigen (anti-HBc) which are not rapid tests.
Table 2 applies to first-line assays for HBsAg and anti-HBc which are rapid tests.
Table 3 applies to confirmatory assays for HBsAg.
Table 4 applies to assays for the hepatitis B virus markers: hepatitis B surface antibodies (anti-HBs), IgM antibody against the hepatitis B core antigen (anti-HBc IgM), antibodies against the hepatitis Be antigen (anti-HBe) and hepatitis Be antigen (HBeAg).
Table 5 applies to qualitative and quantitative NAT devices for HBV deoxyribonucleic acid (DNA).
Table 6 applies to HBV self-tests.
[Blood donor populations shall be investigated from at least two blood donation centres and consist of consecutive blood donations, which have not been selected to exclude first-time donor.]
Performance characteristic | Specimen | Specimen numbers, features, use | Acceptance criteria
Diagnostic sensitivity | Positive specimens |
≥400
anti-HBc: including evaluation of different HBV markers
HBsAg: including different HBV genotypes / subtypes / mutants
anti-HBc or HBsAg: including 25 positive ‘same day’ fresh serum (≤ 1 day after specimen taking)
Overall performance shall be at least equivalent to the comparator device
Seroconversion panels |
HBsAg assays:
≥30 panels
anti-HBc assays:
to be defined when available
diagnostic sensitivity during seroconversion shall represent the state of the art (for anti-HBc this shall be the case if applicable)
Analytical sensitivity | WHO Third International Standard HBsAg (subtypes ayw1/adw2, HBV genotype B4, NIBSC code: 12/226) | | For HBsAg assays: <0,130 IU/ml
Diagnostic specificity | Unselected blood donors (including first-time donors) | ≥5000 | ≥99,5%
Hospitalised patients | ≥200 | Potential limitations for specificity, if any, shall be identified
Cross-reactivity | Potentially cross-reacting specimens |
≥100 in total
(e.g. RF+, from related virus infections, from pregnant women,)
Performance characteristic | Specimen | Specimen numbers, features, use | Acceptance criteria
Diagnostic sensitivity | Positive specimens |
≥400
including evaluation of different HBV markers
including different HBV genotypes / subtypes / mutants
Overall performance shall be at least equivalent to that of the comparator device
Seroconversion panels |
HBsAg assays:
≥30 panels
anti-HBc assays:
to be defined when available
Diagnostic sensitivity during seroconversion shall represent the state of the art (for anti-HBc this shall be the case if applicable)
Diagnostic specificity | Unselected blood donors (including first-time donors) | ≥1000 |
HBsAg assays: ≥ 99 %
anti-HBc assays: ≥ 99 %
Hospitalised patients | ≥200 | Potential limitations for specificity, if any, shall be identified
Cross-reactivity | Potentially cross-reacting specimens |
≥200 specimens from pregnant women
≥100 other potentially cross-reacting specimens in total (e.g. RF+, from related infections)
Performance characteristic | Specimen | Specimen numbers, features, use | Acceptance criteria
Diagnostic sensitivity | Positive specimens |
≥300
Including specimens from different stages of infection
Including 20 ‘high positive’ specimens (>26 IU/ml); 20 specimens in the cut-off range
Correct identification as positive (or indeterminate), not negative
Seroconversion panels | ≥15 seroconversion panels/low titre panels | Diagnostic sensitivity during seroconversion shall represent the state of the art
Analytical sensitivity | WHO Third International Standard for HBsAg, subtypes ayw1/adw2, HBV genotype B4, NIBSC code: 12/226 | |
Diagnostic specificity | Negative specimens | ≥10 false positives as available from the performance evaluation of the first-line assay | No false positive results/ no neutralisation
Cross-reactivity | Potentially cross-reacting specimens | ≥50
Performance characteristic | | anti-HBs | anti-HBc IgM | anti-HBe | HBeAg | Acceptance criteria
Diagnostic sensitivity | Positive specimens |
≥100 vaccinees
≥100 naturally infected persons
≥200
Including specimens from different stages of infection (acute/chronic, etc.)
≥200
Including specimens from different stages of infection (acute/chronic, etc.)
≥200
Including specimens from different stages of infection (acute/chronic, etc.)
≥ 98 %
(for anti-HBc IgM: applicable only on specimens from acute infection stage)
Seroconversion panels | 10 anti-HBs seroconversion panels or follow-up series | When available | When available | When available | Diagnostic sensitivity during seroconversion shall represent the state of the art (for anti-HBc IgM, anti-HBe, HBeAg this shall be the case if applicable)
Analytical sensitivity | Standards | WHO Second International Standard for anti-hepatitis B surface antigen (anti-HBs) immunoglobulin, human NIBSC code: 07/164 | | WHO First International Standard anti-hepatitis B virus e antigen (anti-HBe), PEI code 129095/12 | WHO First International Standard for Hepatitis B Virus e Antigen (HBeAg) PEI code 129097/12 HBe | anti-HBs: < 10 mIU/ml
Diagnostic specificity | Negative specimens |
≥500
Including clinical specimens
≥50 potentially interfering specimens
≥200 blood donations
≥200 clinical specimens
≥50 potentially interfering specimens
≥200 blood donations
≥200 clinical specimens
≥50 potentially interfering specimens
≥200 blood donations
≥200 clinical specimens
≥50 potentially interfering specimens
≥ 98 %
For target sequence amplification devices, a functionality control for each specimen (internal control) shall reflect the state of the art. This control shall as far as possible be used throughout the whole process, i.e. extraction, amplification/hybridisation, detection.
Genotype and/or subtype detection shall be demonstrated by appropriate primer or probe design validation and shall also be validated by testing characterised genotyped specimens.
Potential cross-reactivity of non-target nucleic acid sequences shall be analysed by appropriate primer or probe design validation and shall also be validated by testing selected specimens.
Results of quantitative NAT devices shall be traceable to international standards or calibrated reference materials, if available, and be expressed in international units utilised in the specific field of application.
[Reference: European Pharmacopeia 9.0, 2.6.21 Nucleic acid amplification techniques, Validation.]
Performance characteristic | Specimen | Specimen numbers, features, use | Acceptance criteria
Analytical sensitivity | WHO International Standard HBV DNA (or calibrated reference materials) |
NAT sensitivity and NAT LOD shall be validated by dilution series of reference materials, testing of replicates (minimum 24) at different analyte concentrations, including those with transition from positive to negative results with the respective NAT device.
LOD shall be expressed as 95% positive cut-off value (IU/ml) after statistical analysis (e.g. Probit).
quantitative NAT: definition of lower, upper quantification limit, precision, accuracy,
‘linear’ measuring range, ‘dynamic range’. Reproducibility at different concentration levels
According to the state of the art
HBV genotype sensitivity |
WHO International Reference Panel HBV DNA (HBV genotypes)
all relevant genotypes/subtypes, preferably from international reference materials
potential substitutes for rare HBV genotypes (to be quantified by appropriate methods): plasmids; synthetic DNA
Qualitative NAT: at least 10 specimens/genotype or subtype
Quantitative NAT: dilution series for demonstration of quantification efficiencies
According to the state of the art
Diagnostic sensitivity | Positive specimens reflecting the routine conditions of users (no pre-selection of specimens) |
Quantitative NAT: ≥100
Comparative results with another NAT system shall be generated in parallel
According to the state of the art
Seroconversion panels |
Qualitative NAT: ≥10 panels
Comparative results with another NAT system shall be generated in parallel
According to the state of the art
Diagnostic specificity | Blood donor specimens |
Qualitative NAT: ≥500
Quantitative NAT: ≥100
According to the state of the art
Cross-reactivity | Potentially cross-reacting specimens | | According to the state of the art
Carry-over |
High HBV DNA positive;
HBV DNA negative
At least five runs with alternating high-positive and negative specimens shall be performed during robustness studies. The virus titres of the high positive specimens shall be representative of high virus titres occurring naturally. | According to the state of the art
Detection in relation to antibody status | HBV DNA positives: anti-HBV negative, anti-HBV positive | Pre-seroconversion (anti-HBV negative) and post-seroconversion (anti-HBV positive) specimens | According to the state of the art
Whole system failure rate | HBV DNA low-positive | ≥100 HBV DNA low-positive specimens shall be tested. These specimens shall contain a virus concentration equivalent to three times the 95 % positive cut-off virus concentration. | ≥99% positive
[For each body fluid claimed for use with the device, e.g. whole blood, urine, saliva, etc., the sensitivity and specificity of the device for self-testing in the hands of lay persons shall be defined against the confirmed patient infectious status.] [The result interpretation study shall include reading and interpretation of the test results by at least 100 lay persons with each lay person subjected to reading results covering the specified range of result reactivity levels. The manufacturer shall determine the concordance between lay person reading and professional user reading.] [Tests shall be performed prior to the result interpretation study using whenever possible the specimen type intended by the manufacturer. The tests may be performed on contrived specimens based on the natural matrix of the respective specimen type.] [A higher proportion of the specimens shall be in the low-positive range close to the cut-off or LOD of the test.]
Performance characteristic | Specimens | Number of lay persons
Result interpretation |
Interpretation of results by lay persons reflecting the following range of reactivity levels:
non-reactive
reactive
weak reactive
invalid
≥100
Diagnostic sensitivity | lay persons that are known positive | ≥200
Diagnostic specificity | lay persons that do not know their status | ≥400
lay persons that are at high risk of acquiring the infection | ≥200